← Back to Screener
Bausch Health Companies Inc (BHC)
Price$5.82
Favorite Metrics
Price vs S&P 500 (26W)-14.91%
Price vs S&P 500 (4W)7.02%
Market Capitalization$2.93B
P/E Ratio (Annual)13.59x
All Metrics
P/CF (Annual)1.52x
Book Value / Share (Quarterly)$1.51
P/TBV (Annual)89.02x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)8.11%
Cash Flow / Share (Quarterly)$2.68
Price vs S&P 500 (YTD)-18.88%
Gross Margin (TTM)70.65%
Net Profit Margin (TTM)1.53%
EPS (TTM)$0.42
10-Day Avg Trading Volume0.27M
EPS Excl Extra (TTM)$0.42
Revenue Growth (5Y)5.04%
EPS (Annual)$0.42
ROI (Annual)-2.29%
Gross Margin (Annual)70.65%
Net Profit Margin (5Y Avg)-3.94%
Cash / Share (Quarterly)$3.53
P/E Basic Excl Extra (TTM)13.59x
Revenue Growth QoQ (YoY)9.26%
P/E Normalized (Annual)13.59x
ROA (Last FY)0.60%
Revenue Growth TTM (YoY)6.66%
EBITD / Share (TTM)$7.99
ROE (5Y Avg)-91.99%
Operating Margin (TTM)19.24%
Cash Flow / Share (Annual)$2.68
P/B Ratio3.99x
P/B Ratio (Quarterly)12.76x
Net Income / Employee (Annual)$0
EV / Revenue (TTM)2.11x
Net Interest Coverage (TTM)1.23x
ROA (TTM)0.59%
EV / EBITDA (TTM)7.28x
EPS Incl Extra (Annual)$0.42
Current Ratio (Annual)1.47x
Quick Ratio (Quarterly)0.88x
3-Month Avg Trading Volume0.48M
52-Week Price Return31.61%
EV / Free Cash Flow (Annual)21.83x
P/E Incl Extra (TTM)13.59x
Revenue / Employee (TTM)$1
Tangible BV / Share (Quarterly)$0.61
P/S Ratio (Annual)0.21x
Asset Turnover (Annual)0.39x
52-Week High$11.97
Operating Margin (5Y Avg)13.50%
EPS Excl Extra (Annual)$0.42
CapEx CAGR (5Y)5.66%
Tangible BV CAGR (5Y)-21.06%
26-Week Price Return-10.92%
Quick Ratio (Annual)0.88x
13-Week Price Return-24.16%
Total Debt / Equity (Annual)44.72x
Current Ratio (Quarterly)1.47x
Enterprise Value$21,675.607
Revenue / Share Growth (5Y)3.90%
Asset Turnover (TTM)0.38x
Book Value / Share Growth (5Y)-38.57%
Revenue / Employee (Annual)$1
Inventory Turnover (Annual)1.87x
Pretax Margin (Annual)3.57%
Cash / Share (Annual)$3.53
3-Month Return Std Dev43.72%
Gross Margin (5Y Avg)71.01%
Net Income / Employee (TTM)$0
EBITDA CAGR (5Y)5.64%
EBITDA Interim CAGR (5Y)13.37%
ROE (Last FY)-104.67%
Net Interest Coverage (Annual)1.23x
EPS Basic Excl Extra (Annual)$0.42
P/FCF (TTM)2.15x
Receivables Turnover (TTM)4.57x
EV / Free Cash Flow (TTM)21.83x
Total Debt / Equity (Quarterly)44.72x
EPS Incl Extra (TTM)$0.42
Receivables Turnover (Annual)4.57x
ROI (TTM)-2.25%
P/S Ratio (TTM)0.21x
Pretax Margin (5Y Avg)-2.57%
Revenue / Share (Annual)$27.38
Tangible BV / Share (Annual)$0.12
Forward P/E1.33x
Free OCF CAGR (5Y)4.37%
Price vs S&P 500 (52W)1.78%
P/E Ratio (TTM)13.59x
Year-to-Date Return-17.00%
5-Day Price Return6.32%
EPS Normalized (Annual)$0.42
ROA (5Y Avg)-1.17%
Net Profit Margin (Annual)1.53%
Month-to-Date Return5.19%
Cash Flow / Share (TTM)$1.20
EBITD / Share (Annual)$7.94
Operating Margin (Annual)19.24%
LT Debt / Equity (Annual)44.72x
P/CF (TTM)1.52x
ROI (5Y Avg)-4.82%
P/E Excl Extra (TTM)13.59x
LT Debt / Equity (Quarterly)44.72x
EPS Basic Excl Extra (TTM)$0.42
P/TBV (Quarterly)24.39x
P/B Ratio (Annual)12.76x
Inventory Turnover (TTM)1.87x
Pretax Margin (TTM)3.57%
Book Value / Share (Annual)$1.51
Price vs S&P 500 (13W)-24.85%
Beta1.58x
P/FCF (Annual)2.15x
Revenue / Share (TTM)$27.61
ROE (TTM)-96.76%
52-Week Low$5.96
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
2.44
2.44
2.44
2.44
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
BHCBausch Health Companies Inc | 0.21x | 6.66% | 70.65% | — | $5.82 |
LLYEli Lilly & Co. | 13.08x | 44.70% | 83.04% | 27.59% | $903.99 |
JNJJohnson & Johnson | 5.94x | 7.87% | 67.95% | 14.90% | $234.54 |
ABBVABBVIE INC. | 6.04x | 8.57% | 71.62% | -2.88% | $208.99 |
MRKMerck & Co., Inc. | 4.41x | 1.31% | 78.55% | 21.23% | $115.46 |
AZNAstraZeneca PLC | 5.28x | 8.63% | 81.31% | 21.88% | $200.47 |
NVSNovartis AG | 4.98x | 8.91% | 75.82% | 15.26% | $149.73 |
NVONovo-Nordisk A/S | 3.62x | 6.43% | 80.98% | 20.66% | $40.93 |
ABTAbbott Laboratories | 3.66x | 6.59% | 56.50% | 8.20% | $95.47 |
PFEPfizer Inc. | 2.47x | -1.64% | 75.81% | -3.51% | $27.22 |
BMYBristol-Myers Squibb Co. | 2.47x | -0.22% | 72.63% | — | $58.96 |
About
Bausch Health Companies is a diversified global pharmaceutical and medical device company focused on specialty care markets including gastroenterology, hepatology, neurology, and dermatology. Revenue is driven by its portfolio of branded products across Bausch + Lomb (eye care, largest segment), Salix (gastroenterology), Solta Medical (aesthetics), and other diversified products.